PALO ALTO, Calif.--(BUSINESS WIRE)-- Percutaneous Systems, Inc. (PercSys), which develops and markets innovative devices for facilitating the treatment of kidney stones, today announced that it has appointed Gary Curtis President and Chief Executive Officer. Mr. Curtis is a veteran of more than 30 years in the medical device industry, most recently serving as CEO of Concentric Medical, a pioneering stroke treatment company.
According to Robert S. Behl, PercSys founder and prior CEO, “Gary brings a wealth of medical device management experience to PercSys. There is no better person in the industry to drive our sales growth and continuing innovation. We had an absolutely terrific and successful working partnership when we served together previously at RadioTherapeutics, and we look forward to more of the same.” Behl will now assume the role of Chairman of the PercSys Board.
PercSys is the developer and marketer of the PercSys Accordion® family of kidney and ureteral stone devices for enhancing and simplifying stone procedures. Kidney stones afflict 1.7 million Americans each year, and will impact approximately 5 percent of the adult population, over time. Stone treatment consumes over $2 billion dollars annually in U.S. health care expenditures.
“PercSys is approaching the final stages of the development of the ‘game changing’ MicroStent™ device for patients experiencing the disabling pain of kidney stones, stated Curtis. “I am excited about working with the PercSys team (many of whom I have worked with in the past) in continued market development for the current Accordion family of stone products, while simultaneously refining and preparing to launch the breakthrough MicroStent device.”
Prior to Concentric, Curtis served as President and CEO of RadioTherapeutics Corporation, from its first commercial product launch until its acquisition by Boston Scientific in 2001. Prior to RadioTherapeutics, Curtis served as Executive Vice President, Sales and Marketing, at Fusion Medical; General Manager of the Peripheral Systems Division at Advanced Cardiovascular Systems (ACS), and prior to that, as VP Sales at ACS. Gary formerly held sales and marketing management positions at Synthemed, Valleylab, and Howmedica. He holds a B.S. in biology from the University of California, San Diego, and has served on its Board of Trustees.
About PercSys
PercSys is focused on the development and commercialization of unique and cost-effective single-use devices to facilitate and/or replace every type of current kidney stone treatment modality in a very large, underserved market. The company’s initial product offering, the PercSys Accordion® family of kidney and ureteral stone devices, is currently in limited release in the United States, and is rapidly becoming available in the European Union, Asia, and Latin American countries through exclusive medical specialty distribution partners. More information about PercSys and its innovative Accordion products is available at www.percsys.com.
Contact:
Percutaneous Systems, Inc. Craig Ball, 650-493-4200 Vice President, Sales & Marketing info@percsys.com
